AbbVie (NYSE: ABBV) announces that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie. There are multiple programs in Cerevel’s pipeline across several neurological and psychiatric conditions such as schizophrenia, Parkinson’s disease and mood disorders, where there continues to be significant unmet need for patients. Cerevel’s pipeline is highly complementary to AbbVie’s existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new and better tolerated therapies.
Read the full article: AbbVie Completes Acquisition of Cerevel Therapeutics //
Source: https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-cerevel-therapeutics-302212336.html